Hello, everyone, and how are you this fine morning? Our day got off to a nice start, thanks to a warm and shiny sun enveloping the blissfully quiet Pharmalot campus. Our short people have departed for their respective destinations — the local schoolhouse and gainful employment — and we are busily tending to our own usual tasks — brewing cups of stimulation and hunting for items of interest. This, in fact, brings us to the menu of tidbits assembled below. So please indulge and dig in. Hope you have a smashing day and, as always, do keep in touch. …

Activists gathered for AIDSWatch, the nation’s largest annual constituent-based national HIV/AIDS advocacy conference, heckled CDC director Dr. Robert Redfield after he sidestepped questions about the exclusivity and cost of the HIV prevention drug Truvada, the  New York Daily News tells us. Gilead Sciences (GILD) licenses and makes the pill, but its exclusivity rights means people are paying as much as $1,600 each month for a drug that activists say should be available for $6. AIDS activists want the CDC to pursue royalties.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy